Abstract | CONTEXT: OBJECTIVE: Our objective was to see how early patients, made euthyroid with Telepaque, can be treated with 131I and to compare their short- and long-term outcome with patients treated with 131I, after making them euthyroid with carbimazole and beta-blockers. DESIGN: We conducted a randomized controlled trial. SETTING AND PATIENTS: We studied 200 hyperthyroid patients at a tertiary care teaching institute. INTERVENTIONS: The IA group received Telepaque, 500 mg/d orally, for 7 d and then no medication for 1 wk followed by 131I therapy if radioiodine neck uptake had recovered. The control group received 30-40 mg oral carbimazole daily until patients became euthyroid followed by 131I. MAIN OUTCOME: After 1 wk of Telepaque therapy and 6 wk of carbimazole, almost all patients became clinically and biochemically euthyroid, and 86 and 94% of patients were ready for 131I therapy after 1 and 2 wk off Telepaque, respectively. The cure rate, defined as euthyroid plus hypothyroid, after the first dose of 131I in controls and the IA group was 80 and 76.2%, respectively (P = 0.54). Thirty-two percent among controls and 25% in the IA group became hypothyroid within 1 yr (P = 0.33); thereafter, the annual rate of hypothyroidism was about 2% in both groups. After a mean follow-up duration of 11 yr, 58% of patients in the control group and 51% in the IA group were hypothyroid. CONCLUSIONS:
|
Authors | C S Bal, Ajay Kumar, Prem Chandra |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 90
Issue 12
Pg. 6536-40
(Dec 2005)
ISSN: 0021-972X [Print] United States |
PMID | 16189259
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antithyroid Agents
- Iodine Radioisotopes
- Carbimazole
- Iopanoic Acid
|
Topics |
- Adult
- Aged
- Antithyroid Agents
(therapeutic use)
- Carbimazole
(therapeutic use)
- Female
- Humans
- Hyperthyroidism
(drug therapy, radiotherapy)
- Iodine Radioisotopes
(therapeutic use)
- Iopanoic Acid
(therapeutic use)
- Male
- Middle Aged
- Radiotherapy, Adjuvant
- Treatment Outcome
|